SMMT•benzinga•
Summit Therapeutics' Partner Akeso HARMONi-6/AK112-306 Phase 3 Trial Of Ivonescimab In Combination With Platinum-based Chemotherapy Compared With Tislelizumab Met Its Primary Endpoint Of Progression-Free Survival For Locally Advanced Or Metastatic Squamou
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 23, 2025 by benzinga